Bristol-Myers Squibb Company (BMY) Holdings Decreased by Capital One National Association
Capital One National Association lowered its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 12.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 19,030 shares of the biopharmaceutical company’s stock after selling 2,741 shares during the period. Capital One National Association’s holdings in Bristol-Myers Squibb were worth $1,061,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the business. Blue Chip Partners Inc. raised its holdings in shares of Bristol-Myers Squibb by 0.8% in the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 17 shares in the last quarter. Keel Point LLC raised its holdings in shares of Bristol-Myers Squibb by 0.3% in the 1st quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock valued at $342,000 after acquiring an additional 18 shares in the last quarter. Staley Capital Advisers Inc. raised its holdings in shares of Bristol-Myers Squibb by 0.3% in the 1st quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock valued at $379,000 after acquiring an additional 24 shares in the last quarter. Shayne & CO. LLC raised its holdings in shares of Bristol-Myers Squibb by 0.7% in the 1st quarter. Shayne & CO. LLC now owns 4,017 shares of the biopharmaceutical company’s stock valued at $218,000 after acquiring an additional 27 shares in the last quarter. Finally, Founders Capital Management LLC raised its holdings in shares of Bristol-Myers Squibb by 0.7% in the 1st quarter. Founders Capital Management LLC now owns 4,097 shares of the biopharmaceutical company’s stock valued at $223,000 after acquiring an additional 29 shares in the last quarter. 68.88% of the stock is currently owned by hedge funds and other institutional investors.
BMY has been the topic of several recent analyst reports. Cowen and Company reaffirmed a “hold” rating and issued a $65.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday. Jefferies Group LLC raised their price target on Bristol-Myers Squibb from $66.00 to $72.00 and gave the company a “buy” rating in a report on Monday, September 11th. Vetr raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $62.23 price target on the stock in a report on Wednesday, July 12th. Hilliard Lyons cut Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price target on the stock. in a report on Tuesday, September 12th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $62.66.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares in the company, valued at $2,777,820. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Theodore R. Samuels II acquired 6,000 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The shares were bought at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the transaction, the director now owns 18,000 shares of the company’s stock, valued at $1,006,920. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.
Shares of Bristol-Myers Squibb Company (NYSE BMY) traded up 0.40% during trading on Tuesday, reaching $62.95. The company’s stock had a trading volume of 2,060,812 shares. The company has a 50 day moving average of $58.77 and a 200-day moving average of $55.98. The stock has a market cap of $103.23 billion, a price-to-earnings ratio of 22.99 and a beta of 1.18. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $63.47.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The business had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. During the same period in the prior year, the business posted $0.69 earnings per share. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. Analysts forecast that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be given a dividend of $0.39 per share. The ex-dividend date of this dividend is Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.49%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 56.73%.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.